Key facts
as of Sep 2026- It has raised $3.8B across 3 recorded rounds; the latest was Later Stage VC ($300.0M) in Mar 2026.
- Notable investors include Temasek Holdings, Alphabet, Teachers' Venture Growth, Builders VC, Silver Lake — 8 tracked in total.
- 2 institutional filers report fund marks on Verily Life Sciences across 6 filings.
- Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence~$9per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Verily Life Sciences
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in Verily Life Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
2 filers · latest Feb 20262 SEC-registered funds reported 6 fair-value marks on Verily Life Sciences between Apr 2025 and Feb 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
3 roundsDec 2020PE Growth/Expansion$700.0M▮
Jan 2019PE Growth/Expansion$1.0B▮
About Verily Life Sciences
Developer and manufacturer of healthcare tools and devices designed to understand ways to predict and prevent disease onset and progression. The company offers products including glucose monitors, smart lenses, bioelectronic medicines, surgical robots and precision medicines, enabling its consumers to collect health data in timely decision-making and effective interventions.
- Industry
- Monitoring Equipment
- Sector
- Healthcare
- HQ
- Dallas, TX, United States
- Founded
- 2015
- Employees
- 1,254
- Website
- verily.com/
- Ownership
- Privately Held (backing)